查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2022-2029 年腎臟和泌尿外科設備的全球市場
市場調查報告書
商品編碼
1153821

2022-2029 年腎臟和泌尿外科設備的全球市場

Global Nephrology and Urology Devices Market - 2022-2029
出版日期: | 出版商: DataM Intelligence | 英文 200 Pages | 商品交期: 約2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球腎臟和泌尿外科器械市場預計 2021 年將達到 50.1563 億美元，2029 年將達到 159.4792 億美元，預測期內（2022-2029 年）的複合年增長率據稱將保持在 15.68%。

幹細胞是未分化的細胞，可以通過細胞分裂無限地自我更新。此外，這些細胞可以分化成具有特定功能的更成熟的細胞。幹細胞現在用於治療 80 多種令人頭疼的疾病。腎臟和泌尿外科設備正在通過收集、提取和冷凍保存幹細胞和其他免疫系統細胞來探索未來潛在的醫療用途。

市場動態

人們對乾細胞治療潛力的認識不斷提高，這推動了對這些診斷產品的需求不斷增加。此外，新技術的進步和研發費用的增加也是推動市場增長的因素。所有這些因素都有望推動市場增長。

越來越多的新產品發布和加強研發將推動市場增長。

腎臟和泌尿外科設備的全球市場在很大程度上是由人們對乾細胞治療潛力的認識不斷提高所推動的。此外，幹細胞保存、加工和儲存方面的新技術進步也推動了市場的增長。造血幹細胞移植的增加和基於乾細胞研究的投資增加進一步推動了腎臟和泌尿外科設備的發展。新興經濟體、全球主要疾病負擔的增加、高出生率、GDP 增長和可支配收入的增加為主要參與者提供了市場機會。例如，2021 年 9 月，幹細胞庫和診斷解決方案提供商 LifeCell 宣布其新療法 Mesocel 將獲得印度 DGCI（藥物管制總局）治療 COVID-19 的臨床試驗批准。宣布已收購Mesocel 來源於從捐贈的臍帶組織中獲得的間充質乾細胞。這使得能夠治療患有危及生命的 COVID-19 肺炎和急性呼吸窘迫的患者。臨床試驗將分兩個階段進行。

各種資金、新技術進步以及越來越多的最新創新產品發布導致對這些腎臟和泌尿外科設備的高需求。例如，2021 年 3 月，腎臟和泌尿設備公司 LifeCell 將為銀行會員社區推出其首個服務 StemMatch，旨在提供有關可在 LifeCell 註冊表中匹配的干細胞單元的確切質量和數量的信息。已經開始。

腎臟和泌尿外科設備的高治療和運營成本阻礙了市場增長。

然而，腎臟和泌尿外科設備的高運營成本、幹細胞採集過程中的法律和倫理問題、嚴格的監管框架以及低接受度和認可度可能會阻礙市場的進步。這些幹細胞療法的高成本阻礙了市場增長。據幹細胞治療創新診所 DVC Stem 稱，其 IRB 批准的間充質乾細胞 (MSC) 方案預計成本約為 25,000 美元。

COVID-19 影響分析

疫情對全球金融預期、運營和危機應對策略產生了負面影響。 COVID-19 的爆發嚴重影響了醫療保健行業。由於 COVID，腎臟和泌尿外科設備市場遭受了巨大損失，所有研究和臨床試驗都受到對 COVID 的關注的影響。但現在，市場進入者正在改變他們的長期和短期增長戰略，利用研究市場和創造尖端項目來對抗這一流行病。世界各地正在發生各種倡議、合作和合併，促進了市場的增長。例如，2022 年 8 月，臍帶血再生療法製造商 StemCyte 宣布獲得美國食品和藥物管理局的批准，可以使用臍帶血幹細胞療法對 COVID 後綜合徵進行 2 期臨床試驗。

內容

第 1 章市場研究方法和範圍

  • 調查方法
  • 調查目的和範圍

第 2 章市場定義和概述

第 3 章執行摘要

第四章市場動態

  • 市場影響因素
    • 司機
      • 新產品發布次數增加
      • 增加研發
    • 約束因素
      • 與乾細胞療法相關的高費用
    • 商機
    • 影響分析

第五章行業分析

  • 搬運工的五種力量
  • 未滿足的需求
  • 供應鏈分析
  • 監管分析

第 6 章 COVID-19 分析

  • COVID-19 市場分析
    • COVID-19 之前的市場情景
    • COVID-19 的當前市場情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 總結

第 7 章按類型

  • 透析器
  • 尿路結石治療儀
  • 尿失禁和盆腔器官脫垂裝置
  • 良性前列腺增生治療裝置
  • 內窺鏡設備
  • 其他

第八章應用

  • 腎臟疾病
  • 膀胱疾病
  • 泌尿系統癌症
  • 其他

第 9 章最終用戶

  • 醫院
  • 專科中心
  • 門診手術中心
  • 其他

第10章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第11章競爭格局

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的主要公司名單

第12章公司簡介

  • Medtronic Plc
    • 公司簡介
    • 產品組合和說明
    • 主要亮點
    • 財務摘要
  • Baxter International, Inc.
  • Asahi Kasei Corporation
  • B.Braun Group
  • Boston Scientific Corporation
  • Coloplast AS
  • Dornier MedTech
  • Terumo Corporation
  • Fresenius Medical Care
  • Nipro Corporation

第13章 全球腎臟和泌尿外科設備市場-DataM

簡介目錄
Product Code: DMOT862

Market Overview

The global Nephrology and Urology Devices market was valued at US$ 5,015.63 million in 2021 and is estimated to reach US$ 15,947.92 million by 2029, growing at a CAGR of 15.68% during the forecast period (2022-2029).

Stem cells are undifferentiated cells that can self-renew indefinitely through cell division. These cells can also be distinguished into more mature cells with specific functions. Currently, stem cells are used to treat more than 80 nasty diseases. Nephrology and Urology Devices is collecting, extracting and storing by cryogenically freezing the stem cells and other immune system cells for potential future medical use.

Market Dynamics

The increasing demand for these diagnostic products is due to the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are the advancements in novel technologies and increasing research and development expenditure. All these factors are expected to drive market growth.

The increasing number of novel product launches and the rising research and development will drive market growth.

The global market for Nephrology and Urology Devices is primarily driven by the growing awareness of the therapeutic potential of stem cells. Other factors aiding the market growth are advancements in novel stem cell preservation, processing, and storage technologies. The rise in hematopoietic stem cell transplantation procedures and increasing investments in stem cell-based research further propel Nephrology and Urology Devices. Emerging countries, the rising global burden of major diseases, the large number of newborns, the growth in GDP growth, and disposable income act as market opportunities for key players. For instance, in Sep 2021, LifeCell, a stem cell bank and provider of diagnostic solutions, announced that its novel therapy, Mesocel, got approved for a clinical trial from DGCI, the Drug Controller General of India, for COVID-19 treatment. Mesocel is extracted from mesenchymal stem cells derived from the donated umbilical cord tissue. This can now be used to treat patients with life-threatening COVID-19 pneumonia or acute respiratory distress. The clinical trial will be conducted in 2 phases.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these Nephrology and Urology Devices. For instance, in Mar 2021, LifeCell, a Nephrology and Urology Devices company, launched StemMatch, a first-of-its-kind service for the banking members community as it gives information on the accurate quality and number of stem cell units that are matching available within the LifeCell registry.

The high therapy and operational costs associated with Nephrology and Urology Devices will hamper the market's growth.

However, the high operational costs of Nephrology and Urology Devices and legal and ethical issues during the collection of stem cells, along with stringent regulatory frameworks and lack of acceptance and awareness, may hinder the market progress. The high cost of these stem cell therapies is hindering the market growth. According to DVC Stem, an innovative clinic of stem cell therapy, its mesenchymal stem cell (MSC) protocol that is IRB approved costs around US$25,000.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The Nephrology and Urology Devices market has experienced huge losses due to COVID, as all the research and clinical trials got affected due to the diversion of attention toward COVID. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market's growth. For instance, in Aug 2022, StemCyte, a company manufacturing cord blood regenerative therapeutic, announced that Post-COVID Syndrome's Phase II clinical trial with the help of umbilical cord blood stem cell therapy got approved by U.S. Food and Drug Administration.

Segment Analysis

The umbilical cord-derived stem cells segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The umbilical cord-derived stem cells (UCSTs) segment is the highest market holder in the global Nephrology and Urology Devices market. Cord Blood is affluent in stem cells. Stem cells are developed in the bone marrow and differentiate into different blood cells, which are important in various therapies related to blood disorders, such as sickle cell disease. Umbilical cord blood can be used for gene therapy or transplantation as it's a hematopoietic stem cell Type. Umbilical cord-derived mesenchymal stem cells can be used for inflammatory and immune disease therapy. These can be promising active substances for therapeutic product development as they have a few issues related to safety, availability and ethics.

Umbilical cord-derived stem cells dominate the market due to the rising birth rate and global chronic disease cases. According to the Centre for Disease Control and Prevention, in 2021, approximately 3,659,289 newborn cases were reported in the United States. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market's growth. For instance, in May 2021, Cordlife Group Limited, 1st private cord blood bank in Singapore, entered into a partnership with SingHealth Duke-NUS Academic Medical Centre to test new technology that can increase blood-forming stem cells in number from stored umbilical cord blood that is stored in the first-in-man study in Singapore.

Geographical Analysis

North America holds the largest market share of the global Nephrology and Urology Devices market.

North America dominates the global Nephrology and Urology Devices market, primarily attributed to the rising prevalence of chronic ailments such as leukemia, thalassemia, diabetes, autism and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America's rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the American Cancer Society, in 2022, Around 60.650 estimated novel leukemia cases will occur, out of which 24,000 deaths will occur in the United States.

Moreover, the growing number of product launches is responsible for the market's growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market's growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Feb 2021, American CryoStem Corporation, a biotechnology company at the clinical stage working on autologous cellular therapies, announced its agreement with BioTherapeutics Labs Corp., a company manufacturing umbilical cord tissues that's also FDA-registered.

Competitive Landscape

The Nephrology and Urology Devices market is highly competitive with local and global companies' presence. Medtronic Plc, Baxter International, Inc., Asahi Kasei Corporation, B.Braun Group, Boston Scientific Corporation, Coloplast AS, Dornier MedTech, Terumo Corporation, Fresenius Medical Care, Nipro Corporation and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market's growth. For instance, in May 2022, Medtronic announced the data that shows the advantages of simple blood pressure procedures of symplicity spyral renal denervation system for achieving a targeted range of levels of blood pressure.

Medtronic Plc:

Overview:

Medtronic is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The Company has two operating divisions. It focuses on hematology, immunology, neuroscience, ophthalmology, cardiovascular, respiratory & allergy, and solid tumors. It was established in 1949 and is headquartered in Dublin, Ireland.

Product Portfolio:

MaxCell: MaxCell is StemCyte's proprietary processing method that retains the stem cells in higher volume. It preserves more total nucleated cells than other standard processing procedures, improving engraftment chances.

Key Development: In May 2022, Medtronic and DaVita Inc. announced their intention to make a novel, independent medical device company that will focus on kidney care to increase the treatment experience of patients.

The global Nephrology and Urology Devices market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.

Table of Contents

1. Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. The rising novel product launches
      • 4.1.1.2. Increasing research and development
    • 4.1.2. Restraints:
      • 4.1.2.1. High cost associated with stem cell therapies
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces
  • 5.2. Unmet Needs
  • 5.3. Supply chain Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 7.1.2. Market Attractiveness Index, By Type
  • 7.2. Dialysis devices *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 7.3. Urinary stone treatment devices
  • 7.4. Urinary incontinence & pelvic organ prolapse devices
  • 7.5. Benign prostatic hyperplasia (BPH) treatment devices
  • 7.6. Endoscopy devices
  • 7.7. Others

8. By Application

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.1.2. Market Attractiveness Index, By Application
  • 8.2. Kidney Disease *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 8.3. Bladder Disorder
  • 8.4. Urological Cancer
  • 8.5. Others

9. By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Hospitals *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
  • 9.3. Specialty Centres
  • 9.4. Ambulatory Surgical Centres
  • 9.5. Others

10. By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. The U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.6.1. Germany
      • 10.3.6.2. The U.K.
      • 10.3.6.3. France
      • 10.3.6.4. Italy
      • 10.3.6.5. Spain
      • 10.3.6.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

11. Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of Key Companies to Watch

12. Company Profiles

  • 12.1. Medtronic Plc
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Baxter International, Inc.
  • 12.3. Asahi Kasei Corporation
  • 12.4. B.Braun Group
  • 12.5. Boston Scientific Corporation
  • 12.6. Coloplast AS
  • 12.7. Dornier MedTech
  • 12.8. Terumo Corporation
  • 12.9. Fresenius Medical Care
  • 12.10. Nipro Corporation

LIST NOT EXHAUSTIVE

13. Global Nephrology and Urology Devices Market- DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us